Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cabozantinib
Bladder Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Bladder Mixed Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Cervix Melanoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Clear Cell Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Oropharynx Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Esophageal Melanoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Gallbladder Melanoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Infiltrating Bladder Lymphoepithelioma-Like Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Nested Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Large Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Hypopharynx Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Laryngeal Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Malignant Testicular Leydig Cell Tumor
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Malignant Sertoli Cell Tumor
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Carcinoma Of Urethra
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Osteosarcoma
National Cancer Institute (NCI)P2CCC (53)
Showing 1101 to 1125 of 3,272 assets
PreviousPage 45 of 131Next